A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients. But, oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs.
According to a new study from Fred Hutchinson Cancer Research Center, 53 percent of cancer patients' emergency department visits could be avoided with better symptom management and greater availability of outpatient care tailored to their needs.
University of California San Diego School of Medicine researchers report lesions of the appendix are being over diagnosed as invasive cancer.
Oncoceutics Inc. announced results from the first cohort of its phase II trial for patients with recurrent glioblastoma, which showed median overall survival in the first cohort of 17 patients two times that indicated in the current GBM patient literature.
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic cancer, according to a study at MD Anderson Cancer Center.
A study at MD Anderson Cancer Center revealed new details about how enzyme acetyl-CoA synthetase 2 allows brain tumors to grow despite their harsh surroundings.
Martin Edelman, chair of hematology and oncology at Fox Chase Cancer Center, presented the results of a clinical study testing palbociclib, a drug used to treat breast cancer, in patients with squamous non-small cell lung cancer at the American Society of Clinical Oncology.
Clovis Oncology Inc. announced topline data from the confirmatory phase III ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival by investigator review in each of the three populations studied.
A study from the Austrian Breast & Colorectal Cancer Study Group indicates that women with metastasized breast cancer do not benefit from surgery performed prior to drug treatment. This could cause a paradigm shift in treatment of the disease.
